drug

fianlimab

1 story · latest Jul 30, 2026

Status: Investigational
Code: REGN3767
Trials: 8 registered trials in coverage

Relationships

Developed by Regeneron Pharmaceuticals

Timeline

Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial misses

Jul 30Quarterly updatecemdisiran fianlimab

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.